Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice

Anticancer Research

Volumn 20, Issue 3 A, 2000, Pages 1717-1721

  Golab, Jakub ^a   Stoklosa, Tomasz ^b   Czajka, Anna ^b   Dabrowska, Anna ^b   Jakobisiak, Marek ^b   Zagozdzon, Radoslaw ^b   Wojcik, Cezary ^b   Marczak, Maria ^b   Wilk, Sherwin ^b  

^a HARVARD INSTITUTES OF MEDICINE   (United States)

^b NONE

Author keywords

Antitumor effects; Mice; Proteasome inhibitors; TNF

Indexed keywords

PROTEASOME INHIBITOR; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR VASCULARIZATION;

ACETYLCYSTEINE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; COLONIC NEOPLASMS; CYSTEINE ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; MICE; MICE, INBRED BALB C; MULTIENZYME COMPLEXES; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; SKIN; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033865860     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Tanaka K: Proteasomes: structure and biology. J Biochem 123: 195-204, 1998.
2. Spataro V, Norbury C, Harris AL: The ubiquitin-proteasome pathway in cancer. Brit J Cancer 77: 448-455, 1998.
3. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin- dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 3: 231-234, 1997.
4. Wojcik C, Stoklosa S, Giermasz A, Golab J, Zagozdzon R, Kawiak J, Wilk S, Komar A, Kaca A, Malejczyk J, Jakobisiak M: Apoptosis in L1210 leukaemia cells by an inhibitor of the chymotrypsin-like activity of the proteasome. Apoptosis 2: 244-251, 1997.
5. Wojcik C, Schroeter D, Stoehr M, Wilk S, Paweletz N: An inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces arrest in G2-phase and metaphase in HeLa cells. Eur J Cell Biol 70: 172-178, 1996.
6. Tanimoto Y, Onishi Y, Hashimoto S, Kizaki H: Peptidyl aldehyde inhibitors of proteasome induce apoptosis rapidly in mouse lymphoma RVC cells. J Biochem 121: 542-549, 1997.
7. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV: Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58: 4342-4348, 1998.
8. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999.
9. Lin ZP, Boller YC, Amer SM, Russell RL, Pacelli KA, Patierno SR, Kennedy KA: Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-(Greek small letter script kappa)B activation in drug resistance. Cancer Res 58: 3059-3065. 1998.
10. Beg M, Baltimore D: An essential role for NF-(Greek small letter script kappa)B in preventing TNF-α-induced cell death. Science 274: 782-784, 1996.
11. Delic J, Masdehors P, Omura S, Cosset JM, Dumont J, Binet JL, Magdelenat H: The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human cllronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis. Brit J Cancer 77: 1103-1107, 1998.
12. Wilk S, Figueiredo-Pereira M: Synthetic inhibitors of the multicatalytic proteinase complex (proteasome). Enzyme Protein 47: 306-313, 1993.
13. Golab J, Stoklosa T, Zagozdzon R, Kaca A, Giermasz A, Z. P, Machaj E. Dabrowska A, W. F, W. L, Iwan-Osiecka A, Jakobisiak J: G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma moel in mice. Ann Oncol 9: 63-69, 1998.
14. Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W: Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: anti- angiogenic effect on HPV-harboring tumor-cell lines. Int J Cancer 57: 81-85, 1994.
15. Sidky YA, Auerbach R: Lymphocyte-induced angiogenesis: a quantitative and sensitive assay ofthe graft-vs-host reaction. J Exp Med 141: 1084-1100, 1975.
16. Lasek W, Giermasz A, Kuc K, Wankowicz A, Feleszko W, Golab J, Zagozdzon R, Stoklosa T, Jakobisiak M: Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor α in mice: correlation between in vitro and in vivo results. Int J Cancer 66: 374-379, 1996.
17. Oikawa T, Sasaki T, Nakamura M, Shimamura M, Tanahashi N, Omura S, Tanaka K: The proteasome is involved in angiogenesis. Bichem Biophys Res Comm 246: 243-248, 1998.
18. Lasek W, Feleszko W, Golab J, Stoklosa T, Marczak M, Dabrowska A, Malejczyk M, Jakobisiak M: Antitumor effects of the combination immunotherapy with interleukin 12 and tumor necrosis factor α in mice. Cancer Immunol Immunother 45: 100-108, 1997.
19. Gantt SM, Myung JM, Briones MRS, Li WD, Corey EJ, Omura S, Nussezweig V V, Sinnis P: Proteasome inhihitors block development of Plasmodium spp. Antimicrob Agents Chemother 42: 2731 -2738, 1998.
20. Takaoka M, Okamoto H, Ito M, Nishioka M, Kita S, Matsumura Y: Antihypertensive effect of a proteasome inhibitor in doca-salt hypertensive rats. Life Sci 63: 65-70, 1948.
21. Campbell B, Adams J, Shin YK, Lefer AM: Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol 31: 467-476, 1999.
22. Chandra J, Niemer I, Gilbreath J, Kliche K-O, Andreeff M, Freireich EJ, Keating M, McConkey DJ: Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemia lymphocytes. Blood 92: 4220-4229, 1998.
23. Kupatt IJ, Baumann B, Herr I, Wirth T, Debatin KM: Inhibition of nuclear factor (Greek small letter script kappa)B activation attenuates apoptosis resistnce in lymphoid cells. Blood 91: 4624-4631, 1998.
24. Mikulski SM, Viera A, Deptala A, Darzynkiewicz Z: Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor. Int J Oncol 13: 633-644, 1998.
25. Baldini DE: Multidrug resistance - a multicomplex phenomenon. Nature Med. 3: 378-380, 1997.
26. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS: NF-(Greek small letter script kappa)B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683, 1998.
27. Wu MX, Ao K, Prasad KVO, Wu R, Schlossman SF: IEX-1L, an apoptosis inhibitor involved in NF-(Greek small letter script kappa)B-mediated cell survval. Science 281: 998-100, 1998.
28. Sumitomo M, Tachibana M, Ozu C, Asakura H, Mural M, Hayakawa M, Nakamura H, Takayanagi A, Shimizu N: Induction of apoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated I(Greek small letter script kappa)Bα overexpression. Hum Gene Ther 10: 37-47, 1999,
29. Bakker TR, Reed D, Renno T, Jongeneel CV: Efficient adenoviral transfer of NF-(Greek small letter script kappa)B inhibitor sensitizes melanoma to tumor necrosis factor-mediated apoptosis. Int J Cancer 80: 320-323, 1999.
30. Wang C-Y, Cusack JC, Liu R, Baldwin AS: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nature Med 5: 412-417, 1999.
31. Fanelli M, Minucci S, Gelmetti V, nervi C, Gambacorti-Passerini C, Pelicci PG: Constitutive degradation of PML/RARa through the proteasome pathway mediates retinoic acid resistance. Blood 93: 1477-1481, 1999.
32. Wojcik C, Mlynarczuk I, Hoser G, Kawiak J, Stoklosa T, Golab J, Wilk S: A combination of retinoic acid and proteasome inhibitors for the treatment of leukemias in potentially dangerous. Blood 93: 1827-1828, 1999.